Quarterly ResultApr 29, 2026, 07:31 AM
AZN Q1 Revenue +13% to $15.29B; EPS $1.99; Positive Pipeline Data
AI Summary
AstraZeneca reported strong Q1 2026 results with Total Revenue increasing 13% to $15.29 billion and Reported EPS growing 6% to $1.99. The company saw double-digit growth in Oncology and Rare Disease segments and reconfirmed its full-year 2026 guidance. AstraZeneca also announced positive Phase III readouts for four high-value programs, including two new molecular entities, and closed a strategic collaboration with CSPC Pharmaceuticals involving a $1.2 billion upfront payment.
Key Highlights
- Total Revenue increased 13% (8% CER) to $15,288 million in Q1 2026.
- Reported EPS grew 6% (8% CER) to $1.99; Core EPS grew 4% (5% CER) to $2.58.
- Oncology Product Revenue rose 16% (CER) to $6,797 million.
- Rare Disease Product Revenue increased 15% (CER) to $2,420 million.
- Positive Phase III readouts for tozorakimab (COPD) and efzimfotase alfa (HPP).
- Closed strategic collaboration with CSPC Pharmaceuticals with $1.2 billion upfront payment.
- Reconfirmed FY 2026 guidance for Total Revenue (mid-to-high single-digit % increase) and Core EPS (low double-digit % increase).
- US Total Revenue grew 10% (CER) to $6,205 million.